Cardinal Health (CAH) vs Cencora (COR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cardinal Health (CAH) has outperformed Cencora (COR) over the past year, gaining 30.2% versus a loss of 7.3%. Over five years, CAH leads with a +473.1% price change compared with +182.0% for COR. Cencora is the larger company by market cap ($64.71 billion vs $63.06 billion), about 1.0 times the size, while Cardinal Health is growing revenue faster (+14.2% vs +9.3%).
On valuation, Cencora trades at a lower forward P/E (15.6x vs 18.9x for Cardinal Health). Cardinal Health offers the higher dividend yield (0.75% vs 0.71%). Cardinal Health converts more of its revenue into profit, with a net margin of 0.7% versus 0.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAH | COR |
|---|---|---|
| Share price | $272.81 | $339.09 |
| Market cap | $63.06B | $64.71B |
| 1-day change | +0.17% | -0.63% |
| YTD return | +32.75% | +0.40% |
| 1-year return | +30.23% | -7.27% |
| 5-year return | +473.13% | +182.03% |
| P/E ratio (TTM) | 35.29 | 18.89 |
| Forward P/E | 18.89 | 15.60 |
| EPS (TTM) | $7.73 | $17.95 |
| Dividend yield | 0.75% | 0.71% |
| Annual dividend | $2.05 | $2.40 |
| Revenue (latest FY) | $254.25B | $321.33B |
| Revenue growth (YoY) | +14.23% | +9.31% |
| Net income (latest FY) | $1.71B | $1.55B |
| Gross margin | 3.84% | 3.57% |
| Operating margin | 1.03% | 0.82% |
| Net margin | 0.67% | 0.48% |
| 52-week high | $286.29 | $377.54 |
| 52-week low | $180.45 | $244.82 |
| Distance from 52-week high | -4.71% | -10.18% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +8.09% | +12.78% |
| Average volume | 1.72M | 1.29M |
| Shares outstanding | 231.14M | 190.83M |
| Employees | 58,788 | 47,000 |
| Sector | Health Care | Health Care |
| Industry | Other Pharmaceuticals | Other Pharmaceuticals |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAH has outperformed COR by 37.5 percentage points over the past year.
- Cardinal Health trades at a higher earnings multiple (35.3x vs 18.9x trailing P/E).
About Cardinal Health
CAH stock →Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally.
Health Care · Other Pharmaceuticals · 58,788 employees
About Cencora
COR stock →Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally.
Health Care · Other Pharmaceuticals · 47,000 employees
CAH vs COR FAQ
Which is bigger, Cardinal Health or Cencora?
Cencora (COR) is larger, with a market capitalization of $64.71B compared with $63.06B for Cardinal Health (CAH).
Which stock has performed better over the past year, CAH or COR?
CAH returned +30.23% over the past 12 months, compared with -7.27% for COR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CAH or COR?
COR has the lower trailing P/E at 18.9, versus 35.3 for CAH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Cardinal Health or Cencora?
Cardinal Health has the higher yield at 0.75%, compared with 0.71% for Cencora.
Are Cardinal Health and Cencora in the same industry?
Yes. Both are classified in the Other Pharmaceuticals industry within the Health Care sector.